Table 2. Laboratory findings and treatment of patients

|  | | | **Type 2 Diabetes** | |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Characteristic** | **All patients** (n = 828)1 | **no** (n = 621)1 | **yes** (n = 207)1 | **p value**2 |
| Laboratory findings | WBC (×10−9/L) | 11.0 (7.9, 15.6) | 11.1 (7.9, 15.4) | 10.7 (8.1, 15.9) | 0.71 |
|  | WBC (×10−9/L) |  |  |  | 0.71 |
|  | 4-10 | 294 (37.7%) | 220 (37.7%) | 74 (37.8%) |  |
|  | < 4 | 32 (4.1%) | 22 (3.8%) | 10 (5.1%) |  |
|  | 10 | 454 (58.2%) | 342 (58.6%) | 112 (57.1%) |  |
|  | Neutrophils (×10−9/L) | 9.2 (6.1, 13.8) | 9.3 (6.0, 13.6) | 9.1 (6.4, 14.3) | 0.67 |
|  | Neutrophils (×10−9/L) |  |  |  | 0.37 |
|  | <= 6.3 | 265 (32.0%) | 204 (32.9%) | 61 (29.5%) |  |
|  | 6.3 | 563 (68.0%) | 417 (67.1%) | 146 (70.5%) |  |
|  | Lymphocytes (×10−9/L) | 0.9 (0.6, 1.4) | 0.9 (0.6, 1.4) | 0.9 (0.6, 1.3) | 0.24 |
|  | Lymphocytes (×10−9/L) |  |  |  | 0.69 |
|  | = 1 | 402 (48.6%) | 299 (48.1%) | 103 (49.8%) |  |
|  | < 1 | 426 (51.4%) | 322 (51.9%) | 104 (50.2%) |  |
|  | NLR | 10.3 (5.6, 17.4) | 10.2 (5.7, 16.6) | 10.3 (5.1, 20.0) | 0.38 |
|  | NLR |  |  |  | 0.77 |
|  | < 5.86 | 205 (26.7%) | 152 (26.4%) | 53 (27.5%) |  |
|  | = 5.86 | 564 (73.3%) | 424 (73.6%) | 140 (72.5%) |  |
|  | Platelets (×10−9/L) | 211.0 (105.5, 270.0) | 211.0 (96.8, 268.0) | 211.5 (136.0, 276.0) | 0.39 |
|  | Platelets (×10−9/L) |  |  |  | 0.21 |
|  | = 125 | 604 (72.9%) | 446 (71.8%) | 158 (76.3%) |  |
|  | < 125 | 224 (27.1%) | 175 (28.2%) | 49 (23.7%) |  |
| Blood gas findings | SaO2 (%) | 89.0 (82.0, 93.0) | 89.0 (80.0, 93.0) | 90.0 (84.0, 94.0) | **0.030** |
|  | SaO2 |  |  |  | **0.041** |
|  | = 90 | 401 (48.4%) | 288 (46.4%) | 113 (54.6%) |  |
|  | < 90 | 427 (51.6%) | 333 (53.6%) | 94 (45.4%) |  |
|  | FiO2 (%) | 21.0 (21.0, 40.0) | 21.0 (21.0, 40.0) | 21.0 (21.0, 28.0) | 0.26 |
|  | FiO2 (%) |  |  |  | 0.37 |
|  | 21 (O2 therapy) | 228 (27.5%) | 176 (28.3%) | 52 (25.1%) |  |
|  | 21 | 600 (72.5%) | 445 (71.7%) | 155 (74.9%) |  |
|  | Calculated PaO2:FiO2 ratio | 173.0 (89.8, 278.0) | 162.0 (84.6, 264.5) | 197.0 (108.5, 310.0) | **0.001** |
|  | PaO2:FiO2 ratio |  |  |  | 0.14 |
|  | 200 | 391 (47.2%) | 284 (45.7%) | 107 (51.7%) |  |
|  | <= 200 | 437 (52.8%) | 337 (54.3%) | 100 (48.3%) |  |
|  | PaO2:FiO2 ratio | 3.0 (1.9, 3.9) | 2.9 (1.8, 3.8) | 3.2 (2.3, 4.1) | **0.018** |
|  | PaO2:FiO2 ratio |  |  |  | **0.041** |
|  | 200 | 106 (12.8%) | 88 (14.2%) | 18 (8.7%) |  |
|  | <= 200 | 722 (87.2%) | 533 (85.8%) | 189 (91.3%) |  |
|  | PaO2 (mmHg) | 71.8 (58.3, 91.7) | 71.2 (57.0, 89.9) | 73.1 (61.2, 94.9) | 0.061 |
|  | PaO2 |  |  |  | 0.11 |
|  | = 60 | 617 (74.5%) | 454 (73.1%) | 163 (78.7%) |  |
|  | < 60 | 211 (25.5%) | 167 (26.9%) | 44 (21.3%) |  |
| Treatment | Corticosteroids | 717 (86.6%) | 553 (89.0%) | 164 (79.2%) | **<0.001** |
|  | Anticoagulants | 733 (88.5%) | 549 (88.4%) | 184 (88.9%) | 0.85 |
|  | Antimalarials | 437 (52.8%) | 327 (52.7%) | 110 (53.1%) | 0.90 |
|  | Pronation | 352 (46.4%) | 271 (47.8%) | 81 (42.2%) | 0.18 |
| 1Median (IQR); n (%) | | | | | |
| 2Wilcoxon rank sum test; Pearson's Chi-squared test | | | | | |